Blue Laser Vaporization Effective for Benign Prostatic Hyperplasia
By Lori Solomon HealthDay Reporter
TUESDAY, April 8, 2025 -- Blue laser vaporization alleviates lower urinary tract symptoms while preserving sexual function in patients undergoing benign prostatic hyperplasia (BPH) surgery, according to a study published online March 4 in The Aging Male.
Zun-Jie Hu, from The Affiliated Taian City Central Hospital of Qingdao University in China, and colleagues assessed the impact of 450-nm blue laser vaporization on sexual function in 67 patients (median age, 65 years) undergoing BPH surgery and followed for three months.
The researchers found that blue laser vaporization significantly improved International Prostate Symptom Score, quality of life, and International Consultation on Incontinence Modular Questionnaire for Male Lower Urinary Tract Symptoms (ICIQ-MLUTS) scores. Blue laser vaporization was also significantly associated with a reduction in postvoid residual volume. There were no significant changes seen in the International Index of Erectile Function 5 score, Male Sexual Health Questionnaire for Ejaculatory Dysfunction score, or ICIQ-MLUTS sex score, demonstrating preservation of sexual function after surgery.
"To determine the longevity of these effects, additional clinical data and extended follow-up periods are necessary," the authors write. "The findings present an effective surgical approach for safeguarding sexual function in BPH patients."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-04-09 06:00
Read more

- Women More Vulnerable To Heart Risk Factors
- COVID-19 Vaccination Not Linked to Major Structural Birth Defects
- 'Zero Suicide' Model Leads To Fewer Suicides in Health Systems
- Fasting Outperforms Calorie Cutting, Clinical Trial Says
- Nipocalimab, the First and Only Investigational Treatment to be Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults with Moderate-to-Severe Sjögren’s Disease, has now Received Fast Track Designation
- Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions